, , , ,

Success Story: Completion of the Survey of Immune Response to Coronavirus Disease 2019 Infections (SIM-COVID) Study

Success Story: Completion of the Survey of Immune Response to Coronavirus Disease 2019 Infections (SIM-COVID) Study

Problem Overview

The World Health Organization (WHO) declared the COVID-19 outbreak a Public Health Emergency of International Concern (PHEIC) on January 30th, 2020, and then a pandemic on March 11th, 2020. Estimates of the basic reproductive number (R0), the number of secondary infections expected from a single primary infection, range from 2.2 – 5.7 due in part to the uncertainty surrounding the true number of COVID-19 infections in the population. This uncertainty will have profound effects on COVID vaccine strategies as vaccine coverage/natural immunity coverage thought to stop onward transmission is estimated to be 55% – 82% for R0 values of 2.2 and 5.7, respectively.

Photo by Mary Ann Serote
Two Vysnova staff members at a blood drawing station set-up onboard U.S.S. Ronald Reagan

The Vysnova Impact

Vysnova executed a 12-month cross-sectional serology protocol designed to detect the presence of antibodies to SARS-CoV-2 in DoD personnel working or living in USINDOPACOM AOR via a single or repeated cross-sectional serological surveys in order to estimate the prevalence of COVID-19 infections in these populations. Throughout the study, Vysnova provided full program management office support, including but not limited to risk management, budget, spend plans and burn rates management, travel, and other logistical matters. Vysnova is responsible for providing staff overseas to support on-the-ground activities, coordinating procurement of study supplies from different areas of the world, data management, and other technical assistance.

Within the period of performance, Vysnova worked closely with our client and fully executed the project objectives. Despite the impact of the COVID 19 pandemic, the project objectives have been achieved on schedule and within budget. We successfully conducted 11 recruitment events at 2 study sites in Japan i.e. Yokosuka and Okinawa, enrolled a total of 1081 subjects into the study, collected 2 rapid tests, 1 saliva sample, and 1 blood sample from each subject. Laboratory testing and data analysis have been completed. A manuscript is being developed based on the data obtained from this study.